TJS-010, a New Prescription of Kampa Medicine with Putative Antidepressive and Anxiolytic Properties. : A behavioral study using experimental models for depression and anxiety by Tanra, Andi J. et al.
Hiroshima J. Med. Sci. 
Vol.43, No.4, 145~151, December, 1994 
HIJM 43-18 
TJS-010, a New Prescription of Kampa Medicine with. 
Putative Antidepressive and Anxiolytic Properties. 
-A behavioral study using experimental models for 
depression and anxiety-
Andi J. TANRA, Ariyuki KAGAYA, Nobutaka MOTOHASHI, 
Yosuke UCHITOMI and Shigeto YAMAWAKI 
Department of Psychiatry and Neurosciences, Hiroshima University School of Medicine, 1-2-3 Kasumi, 
Minami-ku, Hiroshima 734, Japan 
ABSTRACT 
We investigated the effect of TJS-010, a new prescription of Kampo or oriental medicine, on 
the locomotor activity and body temperature in rats in order to determine its antidepressive 
and anxiolytic effects. Tetrabenazine(TBZ), which sometimes induces depression in humans, 
decreased the spontaneous locomotion in rats, and attenuated the content of amines in several 
regions in the rat brain when intraperitoneally injected. TJS-010 was orally administered at 
a concentration of 750 mg/kg, and inhibited the locomotor suppression. The content of amines 
was not, however, altered. These results indicate that TJS-010 postsynaptically modulates the 
transmission or transduction. Imipramine, 5mg/kg, also enhanced locomotion in TBZ-treated 
rats, which was similar to the effect of TJS-010. These results suggest that TJS-010 has an 
antidepressive effect. TJS-010 also facilitated the hypothermia induced by subcutaneous injec-
tion of 0.1 mg/kg ( ± )-8-hydroxy-2-(di-N-propylamino)tetralin (8-0H-DPAT), which is known to 
be mediated by serotonin-lA receptors. The hypothermia in the rats via an activation of 
serotonin-lA receptors is often observed with anxiolytic drugs. These results may raise the 
possibility that TJS-010 has an anxiolytic property. TJS-010 may serve as a useful drug for 
the treatment of those who suffer from depressive and anxiety disorders. 
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Many psychotropic drugs such as neuroleptics, 
antidepressants and anxiolytics have beerr 
introduced into clinical practice from 1950s ancli 
their efficacy in the treatment of those who suffer: 
from psychiatric disorders has been widely ac-
cepted. These drugs, however, sometimes induce 
unpleasant side effects. 
similar to that of Untan-to. This similarity sug-
gests to us of the possibility of TJS-010 for a new 
antidepressant or anxiolytic drug. 
Several kinds of traditional oriental medicine 
(Kampo) have been reported to possess psychotro~ 
pie actions. For example, Saiko-ka-ryukotsu-bo~ 
rei-to is effective with few side effects in those 
who are in a state of anxiety or depressive 
mood20). Shimotsu-to improves the cognitive func-
tion and memory in rats27). Moreover, Untan-to is 
often used to treat patients who suffer from anxi-
ety, depressive mood and insomnia. Detailed 
mechanisms of action of Kampo, however, are 
still unknown. TJS-010, a new prescription of 
Kampo, is composed of Hange (pinelliae tuber), 
Bukuryou (hoelen), Chimpi (aurantii nobilis per-
icarpium), Chikujo (phyllostachysis caulis in tae-
niam), Kijitsu (aurantii fructus immaturus), 
Kanzou (glycyrrhizae radix) and Shoukyou (zin-
giberis rhizoma). The composition of TJS-010 is 
Tetrabenazine(TBZ) provides an animal model 
of depression because TBZ is known to precipi-
tate human subjects into depression10). It induces 
the release of monoamines such as dopamine, no-
repinephrine and serotonin into the synaptic cleft 
to cause a decreased level in the brain17,22,29,30), 
and leads to a decrease in locomotor actiyity6·22). 
Several antidepressant drugs improve the TBZ-
induced depletion of monoamine concentration in 
the brain and behavioral depression6,29,30). 
Some kinds of anxiolytics such as buspirone, ip-
sapirone and gepirone have recently been proved 
to be partial agonists for serotonin-lA recep-
tors 18·23), suggesting that the agonistic effect on 
serotonin-lA receptors is responsible for their an-
xiolytic properties. Agonists for serotonin-1 recep-
tors also induce hypothermia in rats and the 
reduction in body temperature is known to be 
functionally mediated by serotonin-lA receptors 
in the central nervous system24·25). 
In this study, we have investigated whether 
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T JS-010 has effects similar to those of antide-
pressants or anxiolytics, using TBZ-induced sup-
pression of locomotion and serotonin-lA receptor 
agonist ( ± )-8-hydroxy-2-(di-N-propylamino)tetral-
in (8-0H-DPAT)-induced hypothermia. 
MATERIALS AND METHODS 
Animals: Male Wistar rats weighing 150-220g 
were obtained from Hiroshima Laboratory Ani-
mals. Rats were housed in cages with free access 
to food and water in an air-conditioned room. 
They were subjected to a 12 hour light/dark cycle 
(light on; 8:30-20:30). 
Administration of drugs: In the TBZ experi-
ments, rats were intraperitoneally injected with 
indicated concentrations of TBZ and locomotion 
was measured immediately. TJS-OlO(generously 
donated by Tsumura & Co.) was orally adminis-
tered 30 min before the injection of TBZ. Imipra-
mine was also orally administered 30 min before 
the injection of TBZ. Rats were subcutaneously 
injected with indicated concentrations of 8-0H-
DPAT. TJS-010 was orally administered 90 min 
before the injection of 8-0H-DPAT. 
Measurement of spontaneous locomotor ac-
tivity: Behavior was measured between 
9:30-17:00, using 2 machines (Animex III-A) si-
multaneously. Spontaneous locomotor activity 
was measured for indicated duration and calcu-
lated with a PT-2 activity meter. 
Measurement of amine contents in rat 
brain: Rats were sacrificed by decapitation and 
their brains were stocked at -80°C until mea-
surement of amine contents. The brains were dis-
sected into frontal cortex(FC), striatum(ST) and 
thalamus/hypothalamus(TH/HT). The tissue was 
homogenized with 0.1 N PCA and 1 mM EDTA, 
and centrifuged at 12000 rpm for 15 min. An ali-
quot of supernatant was then filtrated through a 
chromatodisc (pore size 0.2 µm) and the level of 
monoamines determined by high performance liq-
uid chromatography with electrochemical detec-
tion. The mobile phase was 50 mM phosphate 
buffer (pH 3.2) containing 10 % methanol and 
0.85 mM octanesulfonic acid. 
Measurement of body temperature: Body 
temperature was measured before the injection of 
8-0H-DPAT, and 15 min after the injection, with 
a thermometer inserted into rectum. 
Statistical analysis: Statistical analysis was 
performed by Student's-t test. 
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Fig. 1. Effect of tetrabenazine on spontaneous loco-
motor activity in rats 
Rats were intraperitoneally injected with indicated 
concentrations of TBZ and immediately locomotion 
was measured for 60 min. Data are expressed as % 
of control. n=4-8. Control rats showed the activity 
of 896 ± 85 counts/60min. 
*p<0.05, **p<0.01 vs control. 
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Fig. 2. Time course of tetrabenazine-induced sup-
pression of locomotion in rats 
Rats were treated with lmg/kg tetrabenazine and 
the locomotion was measured for 60 min. n=8. open 
circle: control rats, closed circle: TBZ-treated rats 
*p<0.05, **p<0.01 vs control. 
RESULTS 
Effect of TBZ on spontaneous locomotion 
in rats 
TBZ induced the depletion of spontaneous loco-
motor activity in rats. Fig. 1 shows the dose-de-
pendent inhibition of locomotor activity induced 
by TBZ within 60 min. Intraperitoneal injection 
with 1 mg/kg TBZ attenuated the locomotion 
approximately 50 % of control, and 3 and 6 mg/kg 
TBZ diminished the locomotor activity to about 
TJS-010 on the Model of Depression and Anxiety 147 
20 %. The injection of 1 mg/kg TBZ rapidly de-
creased the locomotion and the inhibition was ob-
vious after 20 min (Fig. 2). 
Effect of TJS-010 and imipramine on the 
locomotion in TBZ-treated rats 
TJS-010, when administered alone, did not 
change locomotor activity(data not shown). How-
ever, TJS-010, at a dose of 750 mg/kg, partly re-
versed behavioral sedation induced by 1 mg/kg 
TBZ. The reversal effect of accumulated locomo-
tion for 60 min by TJS-010 was significant(Fig. 
3). The locomotion after treatment with TJS-010 
was 141.6 ± 7.7 % of TBZ-injected control rats. 
Imipramine(5 mg/kg) was orally administered 
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Fig. 3. Effect of TJS-010 and imipramine on tetra-
benazine-induced suppression of locomotion in rats 
Rats were orally administered 750mg/kg TJS-010 
(TJS) (n=15) or 5mg/kg imipramine (IMI) (n=9). Af-
ter 30 min, rats were treated with lmg/kg tetrabe-
nazine and the locomotion was measured for 60 
min. *p<0.05, vs TBZ 
and the locomotion was measured. Imipramine 
significantly reversed the sedation of locomotion 
induced by TBZ (Fig. 3). The locomotion after 
treatment with imipramine was 139.2±10.5 % of 
TBZ-injected control rats. Imipramine (5 mg/kg) 
did not alter activity in naive rats(data not 
shown). 
Amine contents in rat brain 
The concentration of brain monoamines was de-
termined 120 min after the rats were treated 
with 1 mg/kg TBZ. Treatment with 1 mg/kg TBZ 
attenuated the content of norepinephrine in the 
FC and TH/HT, of dopamine in ST and TH/HT, 
and of serotonin in TH/HT (Table 1). 
The monoamine content was also determined 
after administration of TJS-010 or imipramine in 
the region where TBZ decreased monoamines. 
N orepinephrine content did not change by 
TJS-010 or imipramine administration in FC or 
TH/HT of rat brain (Fig. 4). Either dopamine in 
ST or TH/HT (Fig. 5), or serotonin in TH/HT (Fig. 
6) did not change by TJS-010 or imipramine ad-
ministration. 
Effect of TJS-010 on hypothermia induced 
by 8-0H-DPAT in rats 
Rats were injected with 8-0H-DPAT subcuta-
neously, and their body temperature was mea-
sured. As shown in Fig. 7, 8-0H-DPAT decreased 
the body temperature 15 min after the injection 
in a dose-dependent manner. TJS-010 (750 mg/ 
kg) significantly enhanced the hypothermia in-
duced by 0.1 mg/kg 8-0H-DPAT 15 min after the 
injection when it was orally administered 90 min 
before the injection (Fig. 8). Decrease in tempera-
ture induced by 0.1 mg/kg 8-0H-DPAT was 
1.65 ± 0.26 or 0.89 ± 0.15°C with or without 
TJS-010, respectively. 
Table 1. Effect of TBZ on monoamine concentration on various regions of rat brain 
Monoamine(nmol/g tissue) 
Region Treatment norepinephrine dopamine serotonin 
FC control 0.13±0.01 0.07±0.02 0.80±0.09 
TBZ 0.06±0.03* 0.08±0.02 0.63±0.04 
ST control 0.29±0.02 11.39±1.11 1.27 ± 0.11 
TBZ 0.31±0.04 5.00 ± 0.57** 1.15 ± 0.07 
TH/HT control 1.03±0.05 0.53±0.06 1.79±0.09 
TBZ 0.81±0.07* 0.24 ± 0.02** 1.44± 0.13* 
Rats were injected without or with 1 mg/kg TBZ intraperitoneally and after 2 hours the content of monoamine was 
determined as described in method. 
Each value is the mean± S.E.M. for 8 rats. Statistical analysis was performed by Student's t test. *p<0.05, **p<0.01 
compared with control. 
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Fig. 4. Norepinephrine content in TBZ-treated rat 
brain 
Rats were orally administered 750mg/kg TJS-010 
(n=15) or 5mg/kg imipramine (IMI) (n=9) 30 min 
before injection of lmg/kg TBZ. Norepinephrine 
content was measured 90 min after the injection. 
Data are expressed as % of norepinephrine content 
in each region of TBZ-treated rats without adminis-
tration of TJS-010 or imipramine(0.29 ± 0.06 and 
2.31±0.35 nmol/g tissue in FC and TH/HT, respec-
tively). Vertical bars represent S.E.M. 
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Fig. 5. Dopamine content in TBZ-treated rat brain 
Rats were orally administered 750mg/kg TJS-010 
(n=15) or 5mg/kg imipramine (IMI) (n=9) 30 min 
before injection of lmg/kg TBZ. Dopamine content 
was measured 90 min after the injection. Data are 
expressed as % of dopamine content in each region 
of TBZ-treated rats without administration of 
TJS-010 or imipramine(5.92±1.09 and 0.36 ± 0.04 
nmol/g tissue in ST and TH/HT, respectively). Verti-
cal bars represent S.E.M. 
DISCUSSION 
TBZ reduced the spontaneous locomotor activity 
in rats, as reported in previous papers6,22), but 
the decrease in activity was apparent more rapid-
ly and at lower doses. We injected rats in day-
light whereas rats in previous investigations6,22) 
were injected during dark periods. Rats appear to 
be more sensitive to TBZ at light period. 
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Fig. 6. Serotonin content in TBZ-treated rat brain 
Rats were orally administered 750mg/kg TJS-010 
(n=15) or 5mg/kg imipramine (IMI) (n=9) 30 min 
before injection of lmg/kg TBZ. Serotonin content 
was measured 90 min after the injection. Data are 
expressed as % of serotonin content of TBZ-treated 
rats without administration of TJS-010 or imipra-
mine(l.99 ± 0.10 nmol/g tissue in TH/HT). Vertical 
bars represent S.E.M. 
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Fig. 7. Effect of 8-0H-DPAT on change in body 
temperature in rats 
Rats were subcutaneously injected with various 
doses of 8-0H-DPAT, and after 15 min the tempera-
ture was measured. Data are expressed as change 
in temperature between post-injection and pre-in-
jection. Each value shows the mean of 6 rats. Verti-
cal bars represent S.E.M. 
5-Hydroxytryptophan(5-HTP), a precursor of 
serotonin, is known to inhibit a spontaneous loco-
motor activity as well and this effect might be 
due to the excess of serotonin in the synaptic 
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Fig. 8. Effect of TJS-010 on 8-0H-DPAT-induced 
hypothermia in rats 
Rats were orally administered with 7 50 mg/kg 
TJS-010, and after 90 min they were injected with 
0.1 mg/kg 8-0H-DPAT. Data are expressed as 
change in temperature between post-injection and 
pre-injection. Each value shows the mean of 12 
rats. Vertical bars represent S.E.M. *p<0.05 
compared with 8-0H-DPAT-treated rats. 
cleft14). The facilitation of serotonin transmission 
may be responsible at least in part for the atten-
uation of the locomotion induced by TBZ in rats 
as a previous report has suggested22). The possi-
bility of supersensitivity in serotonin transmis-
sion of affective disorders is documented using 
human platelets13,28) and response to hor-
mones12). However, by further investigation it is 
important to clarify which amine is more impor-
tant for behavioral depression induced by TBZ. 
TJS-010 significantly reversed TBZ-induced de-
crease in spontaneous locomotor activity in rats. 
Imipramine, a prototype of tricyclic antidepres-
sant, also inhibited the effect of locomotion by 
TBZ. Hori and his colleagues reported that imi-
pramine antagonizes TBZ-induced suppression of 
behavior in rats6). Nagayama et al14) have sug-
gested that mianserin, an antidepressant, im-
proves the 5-HTP-induced suppression of 
locomotor activity. Effect of TJS-010 on the lo-
comotion appears similar to those of antidepres-
sants, which suggests that TJS-010 may have an 
antidepressive effect on human patients. Howev-
er, the mechanism of antidepressants has not 
been fully elucidated. Tricyclic antidepressants 
including imipramine have a moderate effect in 
blocking serotonin-2 receptors26) as well as in ser-
otonin uptake inhibition. Based upon the result 
that TJS-010 or imipramine did not alter the con-
tent of amines, we may postulate that TJS-010 
may change a postsynaptic neural transmission 
or transduction and reverse the decrease in loco-
motor activity by TBZ. The effect of imipramine 
on the locomotion in this study may be mediated 
partly through a postsynaptic event as well. It is 
necessary to investigate the relationship between 
behavioral change and neurochemical findings in-
cluding the metabolism of amines . 
Patients with anxiety disorders, especially pan-
ic disorder, have low responsivity of serotonin-lA 
receptor-mediated hypothermic and neuroendo-
crine responses8). A large body of literature is 
available on the efficacy of azapirones such as 
buspirone, ipsapirone and gepirone, in anxiety 
disorder1- 517). Azapirones are presumably espe-
cially suitable for chronic anxiety patients as 
they do not result in an abuse, addiction, depen-
dence or withdrawal symptom l 5,l6,l9) which often 
occurs in benzodiazepine treatment. Azapirones 
show direct effect on serotonin-lA receptors18) 
and the effect seems important for the treatment 
of anxiety. It has been established that 8-0H-
DPAT-induced hypothermia is mediated by post-
synaptic serotonin-lA receptors25>. The 
thermoregulation by azapirones is related to their 
effectiveness as anxiolytics9). In this regard, it 
should be noted that in this study TJS-010 signif-
icantly enhanced 8-0H-DPAT-induced hypother-
mia. This raises the possibility that TJS-010 has 
putative anxiolytic property. The exact mecha-
nism of action sites of TJS-010 on serotonin-lA 
receptor functions is not yet understood. T JS-010 
may act on the 8-0H-DPAT recognition site of the 
receptor directly, facilitate the binding capacity 
allosterically, or increase the responsivity of the 
postreceptor messenger systems. 
The dosage of T JS-010 used in this study is 3 
to 5 folds of the clinical dosage, which appears 
appropriate in order to expect an antidepressive 
or anxiolytic effect clinically, judging from the 
clinical dosage of imipramine. 
TJS-010 is composed of Hange (pinelliae tuber), 
Bukuryou (hoelen), Chimpi (aurantii nobilis per-
icarpium), Chikujo (phyllostachysis caulis in tae-
niam), Kijitsu (aurantii fructus immaturus), 
Kanzou (glycyrrhizae radix) and Shoukyou (zin-
giberis rhizoma). Some of them show CNS effects 
such as respiration and convulsion: immune sys-
tems and intracellular signaling systemsll,2l) 
which may, at least in part, contribute to the re-
versal effect of TJS-010 on TBZ-induced suppres-
sion of the locomotion and synergistic effect of 
hypothermia induced by 8-0H-DPAT. TJS-010 is 
a newly prescribed medicine and is expected to 
improve depressive or anxious states. The pres-
ent findings indicate that TJS-010 inhibits the 
effect of TBZ and enhances the effect of 8-0H-
DPAT, which may suggest that TJS-010 possibly 
has antidepressive and anxiolytic action. 
In conclusion, in this study we have demon-
strated that l)TBZ decreased the spontaneous lo-
comotion in rats and TJS-010 antagonized the 
behavioral suppression induced by TBZ, and that 
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2)8-0H-DPAT reduced the body temperature of 
rats and TJS-010 facilitated the hypothermia in-
duced by 8-0H-DPAT. These results suggest a 
possibility that TJS-010 show antidepressive and 
anxiolytic effects. 
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